Loading...

2,281 posters, 63 videos, 56 audios, 43 topics, 18 sessions, 6,174 authors, 2,323 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

RCOG World Congress 2025

June 23 - 25, 2025 | ExCeL London, UK

EP.1803

Serotonin Syndrome and Intrahepatic Cholestasis of Pregnancy: A Case of Drug Toxicity

Part of Topic

PNMH

Serotonin Syndrome and Intrahepatic Cholestasis of Pregnancy: A Case of Drug Toxicity

Livia Samara, Abigail Oliver

University Hospitals Bristol and Weston NHS Foundation Trust 

•Intrahepatic cholestasis of pregnancy (ICP) affects 0.7% of pregnancies in the UK
•ICP is characterized by pruritus in the absence of a primary skin condition with abnormal bile acid concentrations [1]
•20-80 % of patients with ICP have abnormal liver function tests (LFTs) [2]
•3.3% of pregnant women in the UK are prescribed selective serotonin re-uptake inhibitors (SSRIs) and its prevalence is rising [3,4]
•The increasing use of SSRIs and antipsychotic medications during pregnancy raises concerns about serotonin syndrome, a known complication of this medication

This is characterised by a classic triad, shown in figure 1. [5]

Background:

§32 years old
§G2 P0 (previous termination of pregnancy at 8 weeks)
§History of bipolar disorder, post-traumatic stress disorder and previous suicide attempts
§Medication history – Quetiapine 150 mg OD, duloxetine 120 mg OD
§Booked her pregnancy at 9+3
§Under consultant led care due to mental health history

 

31+4:

§Saw her community midwife and reported itching
§Bloods were taken which showed total bile acids of 82 µmol/L and ALT of 734 U/L

31+5:

§Seen in DAU by consultant
§On review reported 3-day history of itchy hands and feet with no rash which had progressed to all over her body. This was worse at night and in the evenings. She was also feeling nauseous and had on occasion vomited. She denied any other symptoms
§Repeat bloods showed total bile acids of 40 µmol/L and ALT of 848 U/L
§Due to severely deranged LFTs was admitted for further investigation

31+6:

§Reviewed by SpR overnight due to tachycardia and hypertension
§Observations: HR 150, BP 162/95, RR 20, Sp02 98% on air, temperature 36.2
§On review she was agitated and reported a 3-day history of periods of chest heaviness and palpitations occurring 10 times per day
§On examination she was hyperreflexic, 1 beat of clonus in left foot only, dilated pupils and normal tone
§Investigations shown in table 1
§She required a stat dose of labetolol
§Given her medication history and new derangement in liver function in the presence of the classic triad of symptoms she was diagnosed with serotonin syndrome
§Duloxetine dose reduced

32+3:

ALT improving and discharged home

36+3:

§Consultant antenatal clinic review
§Induction of labour booked for 37+3 – 37+5

36+6:

§SRM confirmed

37+0:

§Augmented with oxytocin
§Category 2 caesarean section for abnormal CTG in labour
 

Serotonin syndrome is defined as an excess of serotonin in the central nervous system and is characterised by a triad of neuromuscular excitation, autonomic effects and an altered mental state. It is a clinical diagnosis[5]. It is typically associated with recent increases or overdose of serotonergic medications, such as SSRIs and atipsyhcotics. However, in the setting of liver impairment, drug metabolism may be slowed, leading to elevated drug levels and toxicity. Both duloxetine and quetiapine are metabolized by the liver, and in this case, ICP-induced liver dysfunction likely contributed to drug accumulation, precipitating serotonin syndrome[6]. This is the first reported case of serotonin syndrome in the context of liver dysfunction in ICP. Given the rising number of antenatal patients on SSRIs in the UK, it is important for obstetricians to be familiar with this rare, but potentially life-threatening complication.  

This case demonstrates the need to consider the diagnosis of serotonin syndrome in patients with ICP and abnormal liver function tests on psychiatric medications presenting with unusual symptoms.

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.